April 11, 2019
Coming out of this year’s American College of Cardiology (ACC) meeting, it’s clear that there is growing consensus for using coronary computed tomography angiography (CCTA) as a primary diagnostic strategy for assessing symptomatic patients with coronary artery disease (CAD). There were numerous discussions about whether the 2016 National Institute of Health and Care Excellence (NICE) guidelines putting CCTA as the first test for all stable chest pain patients should be universally adopted, following the recent publications by Hecht, et al in the European Heart Journal and Blaha, et al in the Journal of the American College of Cardiology (JACC). The discussions I engaged in certainly indicated there is no doubt the evidence supports putting CCTA as the frontline test for stable chest pain.
I was also encouraged to see that the CT manufacturers are offering new solutions such as CT scanners that are optimized for cardiac scanning and are compact enough to be housed in outpatient offices. These new offerings will help make CCTA more broadly available.
Specific to the HeartFlow FFRCT Analysis, I wanted to share two new presentations which demonstrate the value of following a CCTA and HeartFlow Analysis pathway.
ADVANCE is a large prospective international multicenter registry that included 5,083 patients at 38 sites, split between North America, the EU, and Japan. In the study, all patients underwent a CCTA. If additional information was needed, the physician ordered a HeartFlow Analysis. The 1-year results showed that the HeartFlow Analysis helped physicians more precisely stratify their patients and deliver more personalized care:
During the value-based healthcare session, Dr. Geoffrey Rose of the Sanger Heart & Vascular Institute presented the findings of incorporating the HeartFlow Analysis in their center. Sanger adopted the HeartFlow Analysis and found the following: